MYOV has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
MYOV has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Myovant Sciences does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.
The historical data trend for Myovant Sciences's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Myovant Sciences Annual Data | ||||||||||||||||
Trend | Mar16 | Mar17 | Mar18 | Mar19 | Mar20 | Mar21 | Mar22 | |||||||||
Shiller PE Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
Myovant Sciences Quarterly Data | ||||||||||||||||||||
Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | |
Shiller PE Ratio | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Myovant Sciences's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Myovant Sciences's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Myovant Sciences's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Myovant Sciences does not have a history long enough to calculate E10. Therefore GuruFocus does not calculate Shiller PE Ratio for this company.
Myovant Sciences (NYSE:MYOV) Shiller PE Ratio Explanation
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Be Aware
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Thank you for viewing the detailed overview of Myovant Sciences's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Sumitomo Chemical Co., Ltd. | 10 percent owner | 7-1, NIHONBASHI 2-CHOME, CHUO-KU, TOKYO M0 103-6020 |
Lauren Merendino | officer: Chief Commercial Officer | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
David C Marek | director, officer: Principal Executive Officer | C/O WEBMD HEALTH CORP., 111 EIGHTH AVENUE, NEW YORK NY 10011 |
Matthew Lang | officer: General Counsel & Corp. Secy. | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Ferreira Juan Camilo Arjona | officer: Chief Medical Officer | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Uneek Mehra | officer: Principal Financial Officer | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Shigeyuki Nishinaka | director | 5281 CALIFORNIA AVENUE, SUITE 100, IRVINE CA 92617 |
Nancy Valente | director | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Terrie Curran | director | C/O MYOVANT SCIENCES INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Frank Karbe | officer: Principal Fin'l & Accounting | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, 9TH FLOOR, BRISBANE CA 94005 |
Kim Sablich | officer: Chief Commercial Officer | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005 |
Hiroshi Nomura | director | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005 |
Sumitovant Biopharma Ltd. | 10 percent owner | C/O ROIVANT SCIENCES, INC., 320 WEST 37TH STREET, 5TH FLOOR, NEW YORK NY 10018 |
Dainippon Sumitomo Pharma Co Ltd | 10 percent owner | 6-8 DOSHOMACHI 2-CHOME, CHUO-KU, OSAKA M0 541-0045 |
Adele M. Gulfo | director | ONE NEENAH CENTER, 4TH FLOOR, P.O. BOX 669, NEENAH WI 54957 |
From GuruFocus
By Value_Insider Value_Insider • 11-16-2022
By PurpleRose PurpleRose • 07-18-2022
By Business Wire Business Wire • 10-24-2022
By Value_Insider Value_Insider • 11-20-2022
By GlobeNewswire GlobeNewswire • 10-24-2022
By Business Wire Business Wire • 10-26-2022
By Value_Insider Value_Insider • 10-18-2022
By Value_Insider Value_Insider • 10-14-2022
By Value_Insider Value_Insider • 10-24-2022
By Value_Insider Value_Insider • 10-24-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.